Drug Information

Drug General Information
Drug ID
D02INX
Former ID
DNCL003794
Drug Name
TD-1211
Drug Type
Small molecular drug
Indication Opioid-induced constipation [ICD9: 564; ICD10:K59.0] Phase 2 [523559]
Company
Theravance
Formula
C26H39N3O4
PubChem Compound ID
67156338
Target and Pathway
Target(s) Mu-type opioid receptor Target Info Modulator [532292]
KEGG Pathway Neuroactive ligand-receptor interaction
Estrogen signaling pathway
Morphine addiction
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Enkephalin release
Pathway Interaction Database IL4-mediated signaling events
Reactome Peptide ligand-binding receptors
G alpha (i) signalling events
WikiPathways TCR Signaling Pathway
GPCRs, Class A Rhodopsin-like
Peptide GPCRs
Opioid Signalling
GPCR ligand binding
GPCR downstream signaling
References
Ref 523559ClinicalTrials.gov (NCT01401985) A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC). U.S. National Institutes of Health.
Ref 532292The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):479-91.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.